Global Royalty Financing Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2010-2018 - ResearchAndMarkets.com

DUBLIN--()--The "Global Royalty Financing Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2010-2018" report has been added to ResearchAndMarkets.com's offering.

The Global Royalty Financing Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2010-2018 report provides comprehensive understanding and unprecedented access to the royalty financing agreements entered into by the worlds leading biopharma companies.

The report provides a detailed understanding and analysis of how and why companies enter business, royalty financing agreements. The focus of the report is on partnerships for royalty assets where partners have entered an agreement to dispose of or acquire said assets. The report provides access to royalty financing deal payment terms as announced between the parties. This data provides useful insight into the payment and other deal terms.

Royalty assets - where a specialist investment company acquires the rights to future royalty payments in return for payment of a lump sum payment to the licensor for the product

Revenue assets - also known as synthetic royalties', where a specialist investment company acquires the rights to a proportion of future revenue streams in return for a lump sum payment to the company

Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered and rights transferred - contract documents provide this insight where press releases and databases do not.

This report provides comprehensive access to royalty and revenue financing deals as announced in the life sciences industry since 2010.

Key Topics Covered:

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in royalty financing dealmaking

Chapter 3 - Overview of royalty financing structure

Chapter 4 - Leading royalty financing deals

Chapter 5 - Top 10 most active royalty financing dealmakers

Chapter 6 - Royalty financing contract documents 2010- 2018

Chapter 7 - Royalty financing agreement directory 2010- 2018

For more information about this report visit https://www.researchandmarkets.com/research/5b6xmt/global_royalty?w=4

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Biotechnology, Pharmaceuticals, Diagnostics

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Biotechnology, Pharmaceuticals, Diagnostics